A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Cetuximab (Primary) ; Urelumab (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 09 May 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top